Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of rever
Author: ["Peter M. Grob","Yunzhen Cao","Elizabeth Muchmore","David D. Ho","Steve Norris","Joseph W. Pav","Cheng-Kon Shih","Julian Adams"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Chimpanzees were challenged with HIV-1IIIB while receiving a short regimen of nevirapine (Viramune), a nonnucleoside inhibitor of HIV-1 reverse transcriptase. The untreated, control chimpanzee developed an infection characterized by seroconversion, viremia in peripheral blood mononuclear cells (PBMCs), and plasma positive for viral RNA. In contrast, the three nevirapine-treated chimpanzees remained negative for all viral markers with the exception of nested polymerase chain reaction (PCR) analysis of PBMCs for viral DNA. Although PBMCs from the three nevirapine-treated chimpanzees tested intermittently positive for viral DNA, this PCR signal disappeared and remained negative for the final five months of the study. These data indicate that orally administered nevirapine provided protection from HIV-1 infection in the chimpanzee model.
Cite this article
Grob, P., Cao, Y., Muchmore, E. et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med 3, 665–670 (1997). https://doi.org/10.1038/nm0697-665
